GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00096159 | Endometrium | AEH | response to virus | 63/2100 | 367/18723 | 3.81e-04 | 4.10e-03 | 63 |
GO:000756810 | Endometrium | AEH | aging | 59/2100 | 339/18723 | 4.00e-04 | 4.28e-03 | 59 |
GO:00519729 | Endometrium | AEH | regulation of telomerase activity | 14/2100 | 47/18723 | 4.51e-04 | 4.76e-03 | 14 |
GO:000806410 | Endometrium | AEH | regulation of actin polymerization or depolymerization | 37/2100 | 188/18723 | 4.57e-04 | 4.80e-03 | 37 |
GO:004232615 | Endometrium | AEH | negative regulation of phosphorylation | 65/2100 | 385/18723 | 4.93e-04 | 5.06e-03 | 65 |
GO:00308329 | Endometrium | AEH | regulation of actin filament length | 37/2100 | 189/18723 | 5.08e-04 | 5.18e-03 | 37 |
GO:000072310 | Endometrium | AEH | telomere maintenance | 28/2100 | 131/18723 | 5.62e-04 | 5.62e-03 | 28 |
GO:19908305 | Endometrium | AEH | cellular response to leukemia inhibitory factor | 22/2100 | 94/18723 | 5.89e-04 | 5.82e-03 | 22 |
GO:00071739 | Endometrium | AEH | epidermal growth factor receptor signaling pathway | 24/2100 | 108/18723 | 7.57e-04 | 7.20e-03 | 24 |
GO:00381279 | Endometrium | AEH | ERBB signaling pathway | 26/2100 | 121/18723 | 7.99e-04 | 7.54e-03 | 26 |
GO:00701984 | Endometrium | AEH | protein localization to chromosome, telomeric region | 10/2100 | 29/18723 | 8.25e-04 | 7.72e-03 | 10 |
GO:00330446 | Endometrium | AEH | regulation of chromosome organization | 36/2100 | 187/18723 | 8.27e-04 | 7.73e-03 | 36 |
GO:00519739 | Endometrium | AEH | positive regulation of telomerase activity | 11/2100 | 34/18723 | 8.45e-04 | 7.82e-03 | 11 |
GO:00322048 | Endometrium | AEH | regulation of telomere maintenance | 19/2100 | 80/18723 | 1.12e-03 | 9.78e-03 | 19 |
GO:00714704 | Endometrium | AEH | cellular response to osmotic stress | 12/2100 | 41/18723 | 1.35e-03 | 1.14e-02 | 12 |
GO:00714807 | Endometrium | AEH | cellular response to gamma radiation | 10/2100 | 31/18723 | 1.48e-03 | 1.23e-02 | 10 |
GO:00321036 | Endometrium | AEH | positive regulation of response to external stimulus | 68/2100 | 427/18723 | 1.82e-03 | 1.44e-02 | 68 |
GO:00712149 | Endometrium | AEH | cellular response to abiotic stimulus | 55/2100 | 331/18723 | 1.85e-03 | 1.46e-02 | 55 |
GO:01040049 | Endometrium | AEH | cellular response to environmental stimulus | 55/2100 | 331/18723 | 1.85e-03 | 1.46e-02 | 55 |
GO:00975818 | Endometrium | AEH | lamellipodium organization | 20/2100 | 90/18723 | 2.01e-03 | 1.56e-02 | 20 |
Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
hsa0517114 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa04610 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0481010 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517115 | Liver | NAFLD | Coronavirus disease - COVID-19 | 111/1043 | 232/8465 | 1.01e-41 | 3.32e-39 | 2.67e-39 | 111 |
hsa046101 | Liver | NAFLD | Complement and coagulation cascades | 35/1043 | 86/8465 | 2.48e-11 | 2.04e-09 | 1.64e-09 | 35 |
hsa0481011 | Liver | NAFLD | Regulation of actin cytoskeleton | 50/1043 | 229/8465 | 3.01e-05 | 7.59e-04 | 6.11e-04 | 50 |
hsa0517122 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa0502014 | Liver | Cirrhotic | Prion disease | 152/2530 | 273/8465 | 1.84e-19 | 8.78e-18 | 5.41e-18 | 152 |
hsa046102 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481021 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa05133 | Liver | Cirrhotic | Pertussis | 37/2530 | 76/8465 | 4.17e-04 | 2.57e-03 | 1.58e-03 | 37 |
hsa04936 | Liver | Cirrhotic | Alcoholic liver disease | 60/2530 | 142/8465 | 1.07e-03 | 5.85e-03 | 3.61e-03 | 60 |
hsa0517132 | Liver | Cirrhotic | Coronavirus disease - COVID-19 | 136/2530 | 232/8465 | 3.28e-20 | 1.82e-18 | 1.12e-18 | 136 |
hsa0502015 | Liver | Cirrhotic | Prion disease | 152/2530 | 273/8465 | 1.84e-19 | 8.78e-18 | 5.41e-18 | 152 |
hsa046103 | Liver | Cirrhotic | Complement and coagulation cascades | 48/2530 | 86/8465 | 4.41e-07 | 5.44e-06 | 3.35e-06 | 48 |
hsa0481031 | Liver | Cirrhotic | Regulation of actin cytoskeleton | 100/2530 | 229/8465 | 5.28e-06 | 5.50e-05 | 3.39e-05 | 100 |
hsa051331 | Liver | Cirrhotic | Pertussis | 37/2530 | 76/8465 | 4.17e-04 | 2.57e-03 | 1.58e-03 | 37 |
hsa049361 | Liver | Cirrhotic | Alcoholic liver disease | 60/2530 | 142/8465 | 1.07e-03 | 5.85e-03 | 3.61e-03 | 60 |
hsa0502022 | Liver | HCC | Prion disease | 195/4020 | 273/8465 | 3.26e-16 | 1.56e-14 | 8.67e-15 | 195 |
hsa0517142 | Liver | HCC | Coronavirus disease - COVID-19 | 167/4020 | 232/8465 | 1.50e-14 | 4.19e-13 | 2.33e-13 | 167 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
C5 | SNV | Missense_Mutation | | c.4015G>C | p.Glu1339Gln | p.E1339Q | P01031 | protein_coding | tolerated(0.2) | probably_damaging(0.946) | TCGA-A2-A0EY-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | adriamycin | SD |
C5 | SNV | Missense_Mutation | | c.759N>T | p.Arg253Ser | p.R253S | P01031 | protein_coding | tolerated(0.5) | benign(0.003) | TCGA-A2-A25E-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | cytoxan | PD |
C5 | SNV | Missense_Mutation | | c.2762N>G | p.Glu921Gly | p.E921G | P01031 | protein_coding | deleterious(0) | possibly_damaging(0.655) | TCGA-A8-A07L-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Chemotherapy | | CR |
C5 | SNV | Missense_Mutation | rs758293412 | c.3422G>A | p.Ser1141Asn | p.S1141N | P01031 | protein_coding | deleterious(0.04) | benign(0.003) | TCGA-A8-A097-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | tamoxiphen | SD |
C5 | SNV | Missense_Mutation | | c.1086N>A | p.Phe362Leu | p.F362L | P01031 | protein_coding | deleterious(0) | possibly_damaging(0.73) | TCGA-A8-A09G-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Unknown | Unknown | SD |
C5 | SNV | Missense_Mutation | | c.1118T>C | p.Val373Ala | p.V373A | P01031 | protein_coding | tolerated(0.08) | benign(0.007) | TCGA-A8-A09Z-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C5 | SNV | Missense_Mutation | novel | c.4517N>T | p.Thr1506Ile | p.T1506I | P01031 | protein_coding | deleterious(0.03) | probably_damaging(0.992) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C5 | SNV | Missense_Mutation | rs369245774 | c.2017N>A | p.Leu673Ile | p.L673I | P01031 | protein_coding | tolerated(0.08) | benign(0.003) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C5 | SNV | Missense_Mutation | novel | c.711N>A | p.Phe237Leu | p.F237L | P01031 | protein_coding | deleterious(0.01) | possibly_damaging(0.6) | TCGA-AN-A046-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
C5 | SNV | Missense_Mutation | novel | c.1643N>A | p.Gly548Glu | p.G548E | P01031 | protein_coding | deleterious(0) | probably_damaging(0.999) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | eculizumab | ECULIZUMAB | 24521109 |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | LFG-316 | TESIDOLUMAB | 24860651 |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | IFX-1 | | |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL1201828 | ECULIZUMAB | |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | inhibitor | CHEMBL2107979 | PEXELIZUMAB | |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | SAND-5 | | 22990692 |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | Ravulizumab | RAVULIZUMAB | |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | NNC-0151-0000-0000 | | |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | ECULIZUMAB | ECULIZUMAB | |
727 | C5 | PROTEASE INHIBITOR, DRUGGABLE GENOME, ENZYME | | ARC-1905 | AVACINCAPTAD PEGOL SODIUM | |